I hope this newsletter finds you and your family well as we start a new and exciting year of innovation and growth at Eyam.

This month we are announcing some impactful news on our journey.

First, we successfully completed three partnering studies that we initially started in September and October. We expect to be able to announce some of the interim results on the Gates Foundation study later in the quarter. While the other two studies results will remain confidential, I can share that the results were very strong and have led to next level negotiations.

We’re also actively planning new partner studies for 2025. We continue to receive strong interest in therapeutic delivery, a confirmation of the versatility of the Gemini Platform. We aim to conduct studies in various animals – including large animals in 2025, which will further strengthen our ability to market and promote our platforms and increase our bargaining power for licensing our platforms.

Second, I’m happy to share that another family office has invested in Eyam. As part of this investment and to encourage additional investment before the Series A, the Eyam Board has authorized improved terms for this current round of investment, increasing the discount to equity to 20%. With the recent partnership studies underway, and a strong pipeline materializing in 2025, now is an excellent time to follow on your investment.

Third, as Eyam continues to evolve and expand the reach of its technologies, we are taking on a new name.

Over the last two years, Eyam has matured and expanded the applications of our technologies. Today, we have validated data for the delivery of both vaccines and therapeutics for infectious and chronic diseases. We have partnered programs running in both human and animal health, and we are actively planning new partnered studies to deploy Eyam’s Gemini Platform for the delivery of cancer vaccines.

With these expanded applications, “Eyam Vaccines and Immunotherapeutics” doesn’t quite capture all that we are. The Eyam Board discussed this topic at our last board meeting and Eyam Shareholders approved a name change at our Annual General Meeting of Shareholders. As we step into the new year, we are re-introducing the company as Eyam Health.

Why the Change?

When we started Eyam in the early days of the COVID-19 pandemic, our mission was clear: to revolutionize vaccine technology and address global health challenges with speed and precision. Over the past four years, we’ve stayed true to that vision while expanding far beyond it.

• Expanding Beyond Vaccines

Eyam began as a vaccine-focused company, but we have since built transformative platforms and enabling technologies that go beyond traditional immunizations. Our Gemini platform and the Jennerator AI Bioinformatics platform have applications in therapeutics, chronic disease treatments, oncology, and even animal health. These breakthroughs have positioned Eyam as an emerging leader in biotechnology innovation.

• A Name That Reflects Our Vision

The name “Eyam Vaccines and Immunotherapeutics” no longer fully represents the breadth of our work. “Eyam Health” captures our expanded mission to deliver health solutions across human and animal health, chronic disease, and global health resilience.

• Clarity and Accessibility:

In our conversations with partners, investors, and clients, we’ve realized that the new name will make it easier for stakeholders to quickly understand the full spectrum of our capabilities. “Health” encompasses everything we are working towards: empowering healthier lives, communities, and ecosystems.

This change reflects not only who we are today but also where we are headed.

What Stays the Same

While our name is evolving, our mission remains constant: to combat current and future global health challenges with next-generation technologies. We continue to honor the legacy of the village of Eyam, whose courage in the face of disease inspires us to this day.

If you will recall, the name Eyam comes from the historic plague village in Debenshire, England. Eyam was a small village of heroic people who confronted the Black Plague with the best weapon they had at the time: by quarantining. The inhabitants of Eyam took care of each other until the end. History now believes the Plague stopped its advance at Eyam and the final wave of the Plague subsided, but not after 90% of the villagers perished.

When we founded the company at the onset of the COVID Pandemic, Eyam’s Founder, Dr. Wilf Jefferies, chose the name to honor the heroic sacrifice of those villagers. Since then, we’ve tried to build a culture taking our values from those same heroic villagers: humility, discernment, courage, and self-sacrifice.

Looking Forward

This name change marks the beginning of an exciting chapter. With Eyam Health, we reaffirm our commitment to innovation and collaboration. Whether it’s continuing  to work on the next groundbreaking vaccine or partnering to solve critical challenges in animal health, we are dedicated to shaping the future of medicine.

What Can You Do?

As we begin 2025, I often get asked at the beginning of the year by our shareholders what can they do to support our mission in the new year. I think there are three main areas:

1) Share our content (newsletter and LinkedIn posts) with potentially interested parties – this could be potential investors, partners, or folks interested in biotech.

2) Make introductions in your network to potential partners, investors, or advisors that are open to learning about Eyam’s impactful technologies and exciting business opportunities.

3) Offer your expertise. Odds are that you’re excellent at what you do and we can learn from you. Reach out and let us know where you might be able to contirbute to help us achieve our ambitious mission.

I believe that one of the undervalued assets of an early stage company is the network and expertise of its investors. Help me to better tap into that in 2025.